|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2
|
Lin DC, Du XL and Wang MR: Protein
alterations in ESCC and clinical implications: a review. Dis
Esophagus. 22:9–20. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Steinmetz MO: Structure and thermodynamics
of the tubulin-stathmin interaction. J Struct Biol. 158:137–147.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Belmont LD and Mitchison TJ:
Identification of a protein that interacts with tubulin dimers and
increases the catastrophe rate of microtubules. Cell. 84:623–631.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cassimeris L: The oncoprotein 18/stathmin
family of microtubule destabilizers. Curr Opin Cell Biol. 14:18–24.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Manna T, Thrower DA, Honnappa S, Steinmetz
MO and Wilson L: Regulation of microtubule dynamic instability in
vitro by differentially phosphorylated stathmin. J Biol Chem.
284:15640–15649. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marklund U, Larsson N, Gradin HM,
Brattsand G and Gullberg M: Oncoprotein 18 is a
phosphorylation-responsive regulator of microtubule dynamics. EMBO
J. 15:5290–5298. 1996.PubMed/NCBI
|
|
8
|
Amayed P, Pantaloni D and Carlier MF: The
effect of stathmin phosphorylation on microtubule assembly depends
on tubulin critical concentration. J Biol Chem. 277:22718–22724.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Niethammer P, Bastiaens P and Karsenti E:
Stathmin-tubulin interaction gradients in motile and mitotic cells.
Science. 303:1862–1866. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Z, Lu H, Shi H, et al: PUMA
overexpression induces reactive oxygen species generation and
proteasome-mediated stathmin degradation in colorectal cancer
cells. Cancer Res. 65:1647–1654. 2005. View Article : Google Scholar
|
|
11
|
Kim JY, Harvard C, You L, et al: Stathmin
is overexpressed in malignant mesothelioma. Anticancer Res.
27:39–44. 2007.PubMed/NCBI
|
|
12
|
Nakashima D, Uzawa K, Kasamatsu A, et al:
Protein expression profiling identifies maspin and stathmin as
potential biomarkers of adenoid cystic carcinoma of the salivary
glands. Int J Cancer. 118:704–713. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang F, Wang LX, He W, Zhu LN, Zhao PR and
Fan QX: Expression of stathmin in esophageal squamous cell
carcinoma and its biological significance. Nan Fang Yi Ke Da Xue
Xue Bao. 30:1552–1557. 2010.(In Chinese).
|
|
14
|
Wang X, Fan QX, Zhao PR and Wang F:
Expression and significance of stathmin in esophageal squamous cell
carcinoma. J Basic Clin Oncol. 120:372–374. 2007.
|
|
15
|
Wang F, Wang LX, Fan QX and Zhao PR:
Inhibitory effects of ASODN of stathmin gene on cultured Eca109
cell lines. J Zhengzhou University (Medical Sciences). 43:414–418.
2008.
|
|
16
|
Wang Q, Xu Y, Zhao X, et al: A facile
one-step in situ functionalization of quantum dots with preserved
photoluminescence for bioconjugation. J Am Chem Soc. 129:6380–6381.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kouzu Y, Uzawa K, Koike H, et al:
Overexpression of stathmin in oral squamous-cell carcinoma:
correlation with tumour progression and poor prognosis. Br J
Cancer. 94:717–723. 2006.PubMed/NCBI
|
|
18
|
Trovik J, Wik E, Stefansson IM, et al:
Stathmin overexpression identifies high risk patients and lymph
node metastasis in endometrial cancer. Clin Cancer Res.
17:3368–3377. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Salvesen HB, Das S and Akslen LA: Loss of
nuclear p16 protein expression is not associated with promoter
methylation but defines a subgroup of aggressive endometrial
carcinomas with poor prognosis. Clin Cancer Res. 6:153–159.
2000.PubMed/NCBI
|
|
20
|
Sun Y, Mi W, Cai J, et al: Quantitative
proteomic signature of liver cancer cells: tissue transglutaminase
2 could be a novel protein candidate of human hepatocellular
carcinoma. J Proteome Res. 7:3847–3859. 2008. View Article : Google Scholar
|
|
21
|
Rana S, Maples PB, Senzer N and Nemunaitis
J: Stathmin 1: a novel therapeutic target for anticancer activity.
Expert Rev Anticancer Ther. 8:1461–1470. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu F, Liu F, Sun YL and Zhao XH:
Significance of STMN1 expression in esophageal squamous cell
carcinoma. World Chin J Digestol. 18:1306–1312. 2010.
|
|
23
|
Sadow PM, Rumilla KM, Erickson LA and
Lloyd RV: Stathmin expression in pheochromocytomas, paragangliomas,
and in other endocrine tumors. Endocr Pathol. 19:97–103. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bjorklund P, Cupisti K, Fryknas M, et al:
Stathmin as a marker for malignancy in pheochromocytomas. Exp Clin
Endocrinol Diabetes. 118:27–30. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xi W, Rui W, Fang L, Ke D, Ping G and
Hui-Zhong Z: Expression of stathmin/op18 as a significant
prognostic factor for cervical carcinoma patients. J Cancer Res
Clin Oncol. 135:837–846. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng AL, Huang WG, Chen ZC, et al:
Identification of novel nasopharyngeal carcinoma biomarkers by
laser capture microdissection and proteomic analysis. Clin Cancer
Res. 14:435–445. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jeon TY, Han ME, Lee YW, et al:
Overexpression of stathmin1 in the diffuse type of gastric cancer
and its roles in proliferation and migration of gastric cancer
cells. Br J Cancer. 102:710–718. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yuan RH, Jeng YM, Chen HL, et al: Stathmin
overexpression cooperates with p53 mutation and osteopontin
overexpression, and is associated with tumour progression, early
recurrence, and poor prognosis in hepatocellular carcinoma. J
Pathol. 209:549–558. 2006. View Article : Google Scholar
|
|
29
|
Gan L, Guo K, Li Y, et al: Up-regulated
expression of stathmin may be associated with hepatocarcinogenesis.
Oncol Rep. 23:1037–1043. 2010.PubMed/NCBI
|
|
30
|
Kuo MF, Wang HS, Kuo QT, et al: High
expression of stathmin protein predicts a fulminant course in
medulloblastoma. J Neurosurg Pediatr. 4:74–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin WC, Chen SC, Hu FC, et al: Expression
of stathmin in localized upper urinary tract urothelial carcinoma:
correlations with prognosis. Urology. 74:1264–1269. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Su D, Smith SM, Preti M, et al: Stathmin
and tubulin expression and survival of ovarian cancer patients
receiving platinum treatment with and without paclitaxel. Cancer.
115:2453–2463. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takahashi K and Suzuki K: Membrane
transport of WAVE2 and lamellipodia formation require Pak1 that
mediates phosphorylation and recruitment of stathmin/Op18 to
Pak1-WAVE2-kinesin complex. Cell Signal. 21:695–703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ravelli RB, Gigant B, Curmi PA, et al:
Insight into tubulin regulation from a complex with colchicine and
a stathmin-like domain. Nature. 428:198–202. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Di Paolo G, Antonsson B, Kassel D,
Riederer BM and Grenningloh G: Phosphorylation regulates the
microtubule-destabilizing activity of stathmin and its interaction
with tubulin. FEBS Lett. 416:149–152. 1997.PubMed/NCBI
|
|
36
|
Moreno FJ and Avila J: Phosphorylation of
stathmin modulates its function as a microtubule depolymerizing
factor. Mol Cell Biochem. 183:201–209. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Antonsson B, Kassel DB, Ruchti E and
Grenningloh G: Differences in phosphorylation of human and chicken
stathmin by MAP kinase. J Cell Biochem. 80:346–352. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gadea BB and Ruderman JV: Aurora B is
required for mitotic chromatin-induced phosphorylation of
Op18/Stathmin. Proc Natl Acad Sci USA. 103:4493–4498. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen PW, Lin SJ, Tsai SC, et al:
Regulation of microtubule dynamics through phosphorylation on
stathmin by Epstein-Barr virus kinase BGLF4. J Biol Chem.
285:10053–10063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Andersen SS: Spindle assembly and the art
of regulating microtubule dynamics by MAPs and Stathmin/Op18.
Trends Cell Biol. 10:261–267. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mistry SJ, Bank A and Atweh GF:
Synergistic antiangiogenic effects of stathmin inhibition and taxol
exposure. Mol Cancer Res. 5:773–782. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Honore S, Pasquier E and Braguer D:
Understanding microtubule dynamics for improved cancer therapy.
Cell Mol Life Sci. 62:3039–3056. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cernuda-Morollon E, Millan J, Shipman M,
Marelli-Berg FM and Ridley AJ: Rac activation by the T-cell
receptor inhibits T cell migration. PLoS One. 5:e123932010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Belletti B, Nicoloso MS, Schiappacassi M,
et al: Stathmin activity influences sarcoma cell shape, motility,
and metastatic potential. Mol Biol Cell. 19:2003–2013. 2008.
View Article : Google Scholar : PubMed/NCBI
|
